TPST-1120

Phase 3Small molecule

Roche

TPST-1120 is one of 14 small molecule programs targeting Systemic Therapy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic TherapyNot yet recruiting

Advanced Liver CancersActive, not recruiting

Systemic TherapyPhase 3

Not yet recruiting

Advanced Liver CancersPreclinical

Active, not recruiting

Competition

Competitive Landscape

8 competitors in Advanced Liver Cancers

#DrugCompanyPhaseTrials

TPST-1120

Roche

Phase 3

1 2

Avastin

Roche

Preclinical

1 3

Tecentriq

Roche

Preclinical

1 4

Actemra

CCelltrion

Preclinical

1 5

Tiragolumab

Roche

Preclinical

1 6

ADG126

Sanofi

Preclinical

1 7

Tobemstomig

Roche

Preclinical

1 8

IO-108

IImmune-Onc Therapeutics

Preclinical

1 9

NKT2152

NNiKang Therapeutics, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

PreclinicalActive, not recruiting

Advanced Liver Cancers

NCT04524871

Q3 2030

Phase 3Not yet recruiting

Systemic Therapy

NCT06680258

Clinical

Trials by Indication[1]

Systemic Therapy1 trial

A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy

Not yet recruiting·TTempest Therapeutics·Phase 3·NCT06680258·740 enrolled

Advanced Liver Cancers1 trial

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)

Active, not recruiting· Roche logo

Roche·Preclinical·NCT04524871·518 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for TPST-1120. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TPST-1120 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TPST-1120. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Roche

TPST-1120

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q3 2030

Trials by Indication[1]

Systemic Therapy1 trial

Advanced Liver Cancers1 trial

References

Drug Info

Quick Facts

Related News